Australia markets open in 3 hours 51 minutes

Cybin Inc. (CYBN)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.35000.0000 (0.00%)
At close: 03:59PM EDT
0.3499 -0.00 (-0.03%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3500
Open0.3500
Bid0.3479 x 1300
Ask0.3480 x 1200
Day's range0.3416 - 0.3501
52-week range0.2100 - 0.7380
Volume1,789,836
Avg. volume5,258,654
Market cap265.892M
Beta (5Y monthly)1.04
PE ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • Business Wire

    Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

    TORONTO, May 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024.

  • Business Wire

    Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

    TORONTO, May 06, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.

  • Business Wire

    Cybin to Participate at the 27th Annual Milken Institute Global Conference

    TORONTO, April 25, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled "Collaborating for Improved Mental Health." The Conference will